Absolutely and thanks! Sorry to be late in seeing this, with post-EULAR travel and all.
Thanks for the comment and obviously very much hear you. I wonder whether we need more data in our patients on clinical protection from vaccine-preventable infections in general - to my limited understanding, it seems that the data we have on influenza vaccination and concomitant DMARDs is not as robust as it could/should be? Money always a consideration I know, even in a non-interventional study, but perhaps the right place for a multi-center platform trial for relevant vaccinations e.g. zoster, influenza, COVID, with both immunogenicity and clinical infection monitored, and biobanking for candidate biomarkers (and ideally geographically-matched healthy comparators)?
Absolutely and thanks! Sorry to be late in seeing this, with post-EULAR travel and all.
Thanks for the comment and obviously very much hear you. I wonder whether we need more data in our patients on clinical protection from vaccine-preventable infections in general - to my limited understanding, it seems that the data we have on influenza vaccination and concomitant DMARDs is not as robust as it could/should be? Money always a consideration I know, even in a non-interventional study, but perhaps the right place for a multi-center platform trial for relevant vaccinations e.g. zoster, influenza, COVID, with both immunogenicity and clinical infection monitored, and biobanking for candidate biomarkers (and ideally geographically-matched healthy comparators)?